Conversion therapy of Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6 in patients with liver metastatic colorectal cancer

ABSTRACT: Interventions: Chemotherapy with Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6. Treatment repeats every 14 days for up to 12 courses (6 courses for Cetuximab plus FOLFIRI and 6 courses for Bevacizumab plus mFOLFOX6) . Liver resection (if possible) Primary outcome(s): Liver resection rate after chemotherapy with Bevacizumab plus mFOLFOX6(R0/R1) Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Colorectal Liver Metastases

PROVIDER: 2620139 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR